Back to News
Market Impact: 0.2
CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law
Source: PR Newswire
Legal & LitigationHealthcare & Biotech
Schall, Brown & Schwartz LLP reminded investors of a securities class-action lawsuit against Capricor Therapeutics (NASDAQ: CAPR), alleging violations of Sections 10(b) and 20(a) of U.S. securities laws. The notice signals legal risk for Capricor, though the provided article excerpt includes no details on alleged damages, class period, or financial impact.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly negative
Sentiment Score
-0.20
Ticker Sentiment
CAPR-0.85
More News
- Paraguay’s Santiago Pena under arrest, new president Pedro Alliana sworn in
- EU charges TikTok over harmful algorithmic 'rabbit hole' effects
- Moderna raises 2026 outlook as CEO says newer vaccines are gaining traction
- How Paraguay’s Ueno collapse is only its latest banking crisis
- Paraguay resumes Pena impeachment proceedings as financial crisis deepens
- Inside the card-grading empire shaping the price of Pokémon cards